Development of Eribulin-based Antibody-Drug Conjugates
Time: 4:30 pm
day: Day One
Details:
- Introduction of Eribulin-based ADC BB-1701 and BB-1705
- Discussion of preclinical results of Eribulin-based ADCs
- Progress of BB-1701 phase 1/2 clinical development
